Showing 7451-7460 of 20885 results for "".
- Gene Linked to Epilepsy, Autism Decoded in New Studyhttps://reachmd.com/news/gene-linked-to-epilepsy-autism-decoded-in-new-study/2462887/SCN2A related-disorders, although rare in the general population, are one of the more common single-gene neurodevelopmental conditions characterized by infantile seizures, autism spectrum disorder and intellectual disabilities
- University of Toronto Scientists Appointed as GSK Chairs Will Advance Drug Delivery Research and Vaccine Education Tools for Healthcare Professionalshttps://reachmd.com/news/university-of-toronto-scientists-appointed-as-gsk-chairs-will-advance-drug-delivery-research-and-vaccine-education-tools-for-healthcare-professionals/2462883/Anna Tadio, professor at the Leslie Dan Faculty of Pharmacy, University of Toronto, and senior associate scientist at The Hospital for Sick Children (SickKids) is the inaugural holder of the GSK Chair in Vaccine Education and Practice-Oriented Tools.
- Air Pollution and Depression Linked with Heart Disease Deaths in Middle-Aged Adultshttps://reachmd.com/news/air-pollution-and-depression-linked-with-heart-disease-deaths-in-middle-aged-adults/2462886/A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is linked with stress and depression, putting under-65-year-olds at increased risk of dying from cardiovascular disease. The research is presented today at ESC Preventive Cardiology 2024, a scient
- LEVEL UP: Upadacitinib Shows Superior Efficacy in ADhttps://reachmd.com/news/level-study-upadacitinib-shows-superior-efficacy-ad/2462870/New topline results evaluating the efficacy and safety of upadacitinib for adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable suggested that treatment with the drug was effective.<
- DPABINet Launches MRI-Based Brain Network Analysis Platformhttps://reachmd.com/news/dpabinet-launches-mri-based-brain-network-analysis-platform/2462862/The human brain, a marvel of complexity, operates as an intricate network where various regions collaborate structurally and functionally. These interactions forge complex patterns that underpin the diverse functionalities of the brain. Understanding these complex functions necessi
- Puzzling Link Between Depression and Cardiovascular Disease Explained at Last: They Partly Develop from the Same Gene Modulehttps://reachmd.com/news/puzzling-link-between-depression-and-cardiovascular-disease-explained-at-last-they-partly-develop-from-the-same-gene-module/2462861/It’s long been known that depression and cardiovascular disease are somehow relate
- Experts Call for Global Genetic Warning System to Combat the Next Pandemic and Antimicrobial Resistancehttps://reachmd.com/news/experts-call-for-global-genetic-warning-system-to-combat-the-next-pandemic-and-antimicrobial-resistance/2462864/Image: Shutterstock.comDuring the Covid-19 pandemic, geno
- Artificial Sweetener Has Potential to Damage Gut, Finds Studyhttps://reachmd.com/news/artificial-sweetener-has-potential-to-damage-gut-finds-study/2462867/Schematic to show the direct (T1R3-dependent) and indirect (bacteria-dependent) impact of the artificial sweetener neotame on the intestinal epithelial cell. Credit: Frontiers in Nutri
- Genetics-Based Universal Vaccine Could Be Effective Against Any Viral Strainhttps://reachmd.com/news/genetics-based-universal-vaccine-could-be-effective-against-any-viral-strain/2462843/Instead of teaching the immune system to create antibodies to fight off a specific virus, the new vaccine would instead teach the body to create small signaling RNA proteins that will shut down harmful viral spread. Photo by Adobe Stock/HealthDay News
- Arrowhead's Plozasiran Could Reach $700M-Plus in Sales by 2032, Meet Major Unmet Need in Dyslipidemiahttps://reachmd.com/news/arrowheads-plozasiran-could-reach-700m-plus-in-sales-by-2032-meet-major-unmet-need-in-dyslipidemia/2462860/With the ink still drying on Arrowhead Pharmaceuticals’ recent announcement of successful 48-week results in a phase 2 trial of its RNAi drug candidate ploz